摘要
目的为国内制药企业进行制剂仿制药FDA申报提供建议,促进我国制药企业的制剂国际化。方法通过对国内代表性的制药企业进行问卷和采访调查,并结合FDA仿制药申请的法规,分析影响国内制药企业申报美国制剂仿制药的主要因素。结果与结论提出促进我国制药企业申报FDA制剂仿制药的建议。
Objective To provide some suggestion to native pharmaceutical firms for pursuing approval of preparation ANDA from FDA,and promote the internationalization of preparation.Methods Through social survey of several native representative pharmaceutical firms,the general condition of native pharmaceutical firms in applying preparation ANDA was studied.Considering the ANDA regulations of FDA,the major constraints to our domestic firms pursuing approval of preparation ANDA from FDA were analyzed and discussed.Results and Conclusion Suggestion for native pharmaceutical firms to pursue approval of preparation ANDA was offered aim to promoting the internationalization of preparation.
出处
《中国药事》
CAS
2011年第1期8-11,共4页
Chinese Pharmaceutical Affairs
基金
国家科技部十一五重大新药创制专项
口服微丸制剂国际化关键技术(编号2009ZX09501-023)